Drug Profile


Alternative Names: Olanzapine/zonisamide SR; OREX-003; Zonisamide SR/olanzapine

Latest Information Update: 12 Jan 2009

Price : $50

At a glance

  • Originator Orexigen Therapeutics
  • Class Benzodiazepines; Isoxazoles; Obesity therapies; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Serotonin uptake inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 02 Oct 2008 Phase-II clinical trials in Obesity in USA (PO)
  • 29 Jul 2008 Preclinical trials in Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top